The National Commission for Indian Medicine (NCISM) has issued an advisory to practitioners of the Indian System of Medicine (ISM) regarding the use of cannabis-containing drugs and self-proclaimed titles as “cannabis specialists.”
The advisory comes in response to concerns raised by the Inter-Ministerial Coordination Committee regarding the illegal sale and promotion of Ayurveda, Siddha, and Unani (ASU) drugs containing cannabis. These drugs are being falsely advertised and prescribed for various ailments on online platforms.
The NCISM has emphasized that registered medical practitioners should refrain from promoting themselves as cannabis specialists. Such claims can be misleading and could lead to the misuse of cannabis-containing drugs.
The advisory serves as a reminder to Indian System of Medicine (ISM) practitioners to adhere to ethical standards and avoid making unsubstantiated claims about the therapeutic benefits of cannabis. It is crucial to prioritize the safety and well-being of patients and ensure that the use of cannabis-containing drugs is guided by evidence-based practices and regulations.
